Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy
Carolina Barbosa Carvalho do Carmo, Ana Luiza Potiguara de Sousa, Gabriel Henrique de Souza Alves Glória, Isabella Serpa Andrade Borges, Alesso Cervantes Sartorelli, Alexandre Nonino · 2026
Read Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy by Carolina Barbosa Carvalho do Carmo, Ana Luiza Potiguara de Sousa, Gabriel Henrique de Souza Alves Glória, Isabella Serpa Andrade Borges, Alesso Cervantes Sartorelli, Alexandre Nonino (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13267896.txt.
Description
Carolina Barbosa Carvalho do Carmo and colleagues present a 2026 case report on a rare tissue disorder that finally answered to a targeted drug. Rosai-Dorfman disease grows immune cells called histiocytes, usually mildly, but sometimes aggressively. Their patient was a 41-year-old woman with two years of spreading disease in neck and chest lymph nodes and her voice box.
Steroids, immune suppressants, other modulators, and chemotherapy all failed her. Gene sequencing of her tissue found a change in MAP2K1, a gene in a major cell growth pathway. She started cobimetinib, a drug that blocks the next step in that same pathway. Her disease cleared fully on scans and exams. The response has lasted over three years since she stopped the drug. The authors urge gene testing in stubborn cases.
Catalog record
| CREATOR | Carolina Barbosa Carvalho do Carmo, Ana Luiza Potiguara de Sousa, Gabriel Henrique de Souza Alves Glória, Isabella Serpa Andrade Borges, Alesso Cervantes Sartorelli, Alexandre Nonino |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12104 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |